Results 171 to 180 of about 35,016 (265)

HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma

open access: yesInternational Journal of Cancer, Volume 158, Issue 11, Page 2957-2971, 1 June 2026.
What's new? Ovarian clear cell carcinoma is highly associated with hypoxia. Hypoxia‐inducible factor 2A (HIF2A) is a key regulator of hypoxic responses, but its role in ovarian clear cell carcinoma remains unclear. This study demonstrated the unfavorable prognostic significance of HIF2A expression in ovarian clear cell carcinoma.
Mengxin Jiang   +15 more
wiley   +1 more source

Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion. [PDF]

open access: yesBreast Cancer Res Treat
Lee TH   +11 more
europepmc   +1 more source

Assessing Lymph Node Metastasis Risk in Patients With Mucosal Gastric Cancer: A Comparison of the WHO and Japanese Criteria and Implications for Endoscopic Submucosal Dissection

open access: yesJGH Open, Volume 10, Issue 6, June 2026.
ABSTRACT Background and Aim Endoscopic submucosal dissection (ESD) is an established treatment for early gastric cancer. However, concerns remain regarding the risk of lymph node metastasis (LNM) under expanded criteria and its applicability across different populations. This study assessed LNM risk in patients with mucosal gastric cancer using WHO and
Jane Chungyoon Kim   +8 more
wiley   +1 more source

Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective

open access: yesJEADV Clinical Practice, Volume 5, Issue 2, Page 402-414, June 2026.
Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy